Efficienty of vaccination in patients with cancer who are treated with chemotherapy.

Response to influenza vaccination in lymphoma patients treated with CHOP and rituximab.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON23415

Enrollment

160

Registered

2011-11-18

Start date

2012-09-01

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lymphoma, non-hodgkins lymphoma, NHL, vaccination, influenza, humoral response, rituximab. lymfoom, non-hodgekin's lymfoma, NHL, vaccinatie, influenza, humorale respons, rituximab.

Interventions

Influenza vaccination.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with non-Hodgkin’s lymphoma, treated with rituximab (with a range of 6-12 cycles) and who are in remission; 2. Completion of rituximab therapy in the last twelve months before start of the study; 3. Age ≥ 18 years; 4. Signing of informed consent. Controls: 1. Age, sex and co-morbidity matched control who has an indication for influenza vaccination.

Exclusion criteria

Exclusion criteria: 1. Completion of rituximab therapy 7-8 months before start of the study; 2. Fever at time of vaccination; 3. Previous/known allergic reaction to any of the components of the vaccines given. Controls: 1. Immunocompromised persons will be excluded (for example immunosuppressive medication).

Design outcomes

Primary

Measure	Time frame
Percentage responders.	—

Secondary

Measure	Time frame
Immunesystem components (amount of memory Bcells, lymphocyte sbsets etc).	—

Contacts

Public ContactM. Rab

Koekoekslaan 1

m.rab@antoniusziekenhuis.nl+31 (0)88 3203000

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)